We are live on ! Find out more
ABMD

Abiomed Inc

Delisted

ABMD was delisted on the 21st of December, 2022.

527 hedge funds and large institutions have $16B invested in Abiomed Inc in 2018 Q2 according to their latest regulatory filings, with 153 funds opening new positions, 158 increasing their positions, 170 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

428% more first-time investments, than exits

New positions opened: 153 | Existing positions closed: 29

40% more funds holding in top 10

Funds holding in top 10: 1521 (+6)

40% more capital invested

Capital invested by funds: $11.4B → $16B (+$4.57B)

30% more funds holding

Funds holding: 405527 (+122)

7% less repeat investments, than reductions

Existing positions increased: 158 | Existing positions reduced: 170

21% less call options, than puts

Call options by funds: $167M | Put options by funds: $212M

Holders
527
Holders Change
+122
Holders Change %
+30.12%
% of All Funds
12.02%
Holding in Top 10
21
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+40%
% of All Funds
0.48%
New
153
Increased
158
Reduced
170
Closed
29
Calls
$167M
Puts
$212M
Net Calls
-$45.4M
Net Calls Change
-$39.3M

ABMD Hedge Fund Activity: Q2 2018 in Review

527 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Abiomed Inc (ABMD) for Q2 2018, worth a combined $16B — up 40% from $11.4B a quarter earlier.

Buyers outnumbered sellers: 153 funds opened new ABMD positions and 29 closed out — a net gain of 124 holders — while 158 added to existing stakes and 170 trimmed.

The largest buyer was Vanguard Group, adding an estimated $297M. The largest seller was BlackRock, cutting an estimated $315M.

  • 527 institutional investors held Abiomed Inc (ABMD) as of Q2 2018, up from 405 in Q1 2018.
  • Funds reported $16B of Abiomed Inc stock for Q2 2018, up 40% quarter-over-quarter.
  • 153 funds opened new Abiomed Inc positions in Q2 2018 and 29 closed out, a net change of +124 holders.
  • The largest Abiomed Inc buyer in Q2 2018 was Vanguard Group, an estimated $297M added.
  • The largest Abiomed Inc seller in Q2 2018 was BlackRock, an estimated $315M sold.

Based on aggregated 13F filings for Q2 2018.